SPL 0.00% 10.5¢ starpharma holdings limited

From the BP report summary --. COVID-19 has impacted recruitment...

  1. 2,063 Posts.
    lightbulb Created with Sketch. 303
    From the BP report summary --

    . COVID-19 has impacted recruitment in Phase 2 DEP-trials,
    however sites have reinitiated
    recruitment (London sites a bit slower than regional UK sites) and at this
    stage results from all the trials are expected within the next 6-7 months,
    which would serve as significant re-rating catalysts for the stock.

    I would suggest this info has come from SPL HQ
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.